Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 11:48 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 457–480 of 1,124 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Influenza Virus Vaccine Clear all

Conditions: Grippe, Influenza, Vaccines
Interventions: pdmFlu vaccine, Placebo, Licensed influenza vaccine; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 84 Years
Enrollment: 157 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 3
States / cities: New Haven, Connecticut • Hollywood, Florida • New York, New York

Conditions: Influenza A
Interventions: MHAA4549A, Placebo; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 38
States / cities: Athens, Alabama • Costa Mesa, California • Fountain Valley, California + 32 more

Conditions: Seasonal Influenza
Interventions: VXA-A1.1; Biological
Lead sponsor: Vaxart; Industry
Eligibility: 18 Years to 49 Years · Male only
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Pregnancy, Influenza
Interventions: Quadrivalent Influenza Vaccine (QIV); Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 244 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2019
U.S. locations: 5
States / cities: San Diego, California • Albany, New York • Columbus, Ohio + 2 more

Conditions: Influenza
Interventions: oseltamivir [Tamiflu]; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 1 Year to 12 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 36
States / cities: Los Angeles, California • Oakland, California • Aurora, Colorado + 30 more

Conditions: Influenza Infection
Interventions: VAX102 [Flagellin.HuM2e], Placebo; Biological
Lead sponsor: VaxInnate Corporation; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 2
States / cities: Lenexa, Kansas • Galveston, Texas

Conditions: Influenza
Interventions: Fluzone®, FluMist®; Biological
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 49 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Stanford, California

Conditions: Influenza, Human, Pregnancy, Birth Defect
Interventions: Flucelvax Trivalent Influenza Vaccine, Flucelvax Quadrivalent Influenza Vaccine; Biological
Lead sponsor: Seqirus; Industry
Eligibility: Female only
Enrollment: 692 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Wilmington, North Carolina

Conditions: Influenza A H3N2, Influenza A H1N1
Interventions: FLU-IGIV, Placebo for FLU-IGIV; Biological · Other
Lead sponsor: Emergent BioSolutions; Industry
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 42
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 34 more

Conditions: Influenza
Interventions: CAIV-T, Liquid; Biological
Lead sponsor: MedImmune LLC; Industry
Eligibility: 6 Months to 18 Months
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2001
U.S. locations: 1
States / cities: Monroe, Wisconsin

Conditions: Influenza, Human
Interventions: Reminder; Behavioral
Lead sponsor: Geisinger Clinic; Other
Eligibility: 18 Years and older
Enrollment: 77,482 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: Danville, Pennsylvania

Conditions: Influenza
Interventions: Influenza vaccine; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 139 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Influenza A Virus, H7N9 Subtype
Interventions: H7N9 Anhui 2013/AA ca, Inactivated subvirion H7N9 vaccine; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 50 Years to 70 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2014
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Influenza
Interventions: Live attenuated Influenza vaccine, Trivalent Influenza Vaccine, TIV followed by LAIV, LAIV followed by TIV; Biological
Lead sponsor: University of Rochester; Other
Eligibility: 2 Years to 9 Years
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2013
U.S. locations: 2
States / cities: Lebanon, New Hampshire • Rochester, New York

Conditions: Influenza
Interventions: AS03, Influenza Virus Vaccine, Monovalent A/H1N1 A/California/7/2009 NYMC X-179A; Drug · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 789 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 7
States / cities: Stanford, California • Decatur, Georgia • Iowa City, Iowa + 3 more

Conditions: Influenza
Interventions: VAL-339851, Placebo; Biological · Other
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 156 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Miami, Florida

Conditions: COVID-19, Influenza A, Influenza Type B
Interventions: Panbio™; Diagnostic Test
Lead sponsor: Abbott Rapid Dx; Industry
Eligibility: Not listed
Enrollment: 903 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 1
States / cities: Easley, South Carolina

Conditions: H5N1 Influenza
Interventions: H5N1 Vaccine; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 22 Years to 54 Years
Enrollment: 69 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Influenza
Interventions: Text message reminder; Behavioral
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 6 Months to 18 Years
Enrollment: 228,361 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Influenza
Interventions: FluBlok, Fluzone, FluCelVax, Fluzone HD; Biological
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years to 49 Years
Enrollment: 413 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2021
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Influenza
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 6 Years and older
Enrollment: 180 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 4
States / cities: Decatur, Georgia • St Louis, Missouri • Cincinnati, Ohio + 1 more

Conditions: Infertility, Recurrent Miscarriage
Interventions: Influenza Vaccine, Sterile Saline; Biological · Other
Lead sponsor: Center for Human Reproduction; Other
Eligibility: 21 Years to 45 Years · Female only
Enrollment: 126 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: COVID-19, Influenza A, Influenza Type B
Interventions: Panbio™; Diagnostic Test
Lead sponsor: Abbott Rapid Dx; Industry
Eligibility: Not listed
Enrollment: 1,129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Fever After Vaccination, Fever, Febrile Seizure
Interventions: PCV13, DTaP, IIV; Biological
Lead sponsor: Duke University; Other
Eligibility: 12 Months to 16 Months
Enrollment: 221 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 3
States / cities: Oakland, California • Atlanta, Georgia • Durham, North Carolina

Search by objective public record fields.

A Study to Learn How Safe, Tolerable and Capable of Producing an Immune Response is, a Modified RNA Vaccine Against Pandemic Influenza

A Study of MHAA4549A as Monotherapy for Acute Uncomplicated Seasonal Influenza A in Otherwise Healthy Adults

Immunogenicity of Seasonal Influenza by Delivery Directly to Ileum

Sanofi Pasteur Quadrivalent Influenza Vaccine (QIV) Pregnancy Registry

A Study of Intravenous Tamiflu (Oseltamivir) in Children With Influenza

Phase I Safety and Immunogenicity Study of VAX102 [Flagellin.HuM2e] Influenza Vaccine in Healthy Adults

Adaptive Immune Responses and Repertoire in Influenza Vaccination and Infection (SLVP031)

Flucelvax (TIVc or QIVc) Pregnancy Registry

Exploring Safety & Clinical Benefit of Anti-Influenza Immunoglobulin Intravenous in Hospitalized Adults With Influenza A

Trial to Investigate Viral Shedding in Healthy Children Vaccinated With Vaccine Virus Liquid (CAIV-T)

Personalized Nudging to Increase Influenza Vaccinations

Influenza Vaccine in Lung Transplant Patients - Persistence of Antibodies

Evaluating the Safety and Immunogenicity of a H7N9 Vaccine for the Prevention of Influenza H7N9 Disease in Adults 50 to 70 Years Old

Effect of Age and Prior Immunity to Response to Seasonal Influenza Vaccines in Children

Sanofi H1N1 Influenza Vaccine Administered at Different Dose Levels With and Without AS03 Adjuvant in Healthy Adult and Elderly Populations

Safety, Tolerability, and Immunogenicity of VAL-339851 in Healthy Adult Subjects

Clinical Evaluation of the Panbio™ COVID-19/Flu A&B Rapid Panel Professional Use Device and the Panbio™ COVID-19/Flu A&B Rapid Panel Self-Test Device

Evaluating the Safety and Immune Response to an H5N1 Influenza Vaccine in People Who Have Previously Received an H5N1 or H7N3 Influenza Vaccine and in People Who Have Never Received a Live Attenuated Influenza Vaccine

Influenza Reminder Text-Messaging

Comparison of Three Licensed Influenza Vaccines

Evaluation of Influenza-Specific Immune Responses in Children and Adults During the 2010-2011 Influenza Season in the U.S.

Effect of Influenza Vaccination on Donor Egg Recipient Outcomes

Clinical Evaluation of the Panbio™ COVID-19/Flu A&B Rapid Panel Professional Use Product Using Mid-Turbinate Nasal Swabs

Fever After Simultaneous Versus Sequential Vaccination in Young Children